Contact usContact us

The Company

Domain Therapeutics, a French and Canadian privately-held biopharmaceutical company, is using transmembrane and G Protein-Coupled Receptor (GPCR) targeting for the discovery and development of innovative therapeutics for the treatment of Central Nervous System (CNS) diseases and cancer.

Using its commercially proven candidate discovery engine (Takeda, Merck Serono and ONO Pharmaceutical), Domain has created a pipeline of high-value projects and partnerships. Validating this approach, two projects discovered by Domain Therapeutics technologies are planned to enter clinical Phase I in early and late 2016.

Domain Therapeutics applies a multi-string corporate strategy to grow its business through:

  • validation of its technologies through collaborative partnerships with Pharma/Biotechs,
  • generation of an internal pipeline of 1st in class drug candidates for high unmet needs in CNS and oncology,
  • valuation of its preclinical assets through spin-out vehicles, financed by leading investment funds or supported by development-only companies.

Domain Therapeutics
Last News

DECEMBER 3, 2015

Domain will attend the 34th JP MORGAN Annual Healthcare Conference on January 10-14, 2016 in San Fransisco, CA (USA)

December 1, 2015

PeptiMimesis, a breakthrough approach to the development of oncology therapies, from Conectus Alsace’s maturation investments

View the press release... 

NOVEMBER 9, 2015

Domain will attend the BIOFIT 2015 Convention, on December 1-2, 2015 in Strasbourg (France)

Visit the link...

September 14, 2015

Domain will attend the BIO Europe Convention, on November 2-4, 2015 in Munich

Visit the link...